Linaclotide in constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: a profile of its use in the USA

被引:0
|
作者
McKeage K. [1 ]
Lyseng-Williamson K.A. [1 ]
机构
[1] Springer, Private Bag 65901, Mairangi Bay, Auckland
关键词
D O I
10.1007/s40267-017-0448-0
中图分类号
学科分类号
摘要
Linaclotide (Linzess®) is a synthetic guanylate cyclase C agonist that acts locally in the gastrointestinal tract to increase intestinal fluid levels, increase colonic transit, and reduce peripheral pain. In adults with constipation-predominant irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC), once-daily oral linaclotide 290 µg (IBS-C), or 145 or 72 µg (CIC), significantly improved stool frequency and consistency, abdominal pain and bloating, and health-related quality-of-life. Linaclotide is generally well tolerated and, consistent with its therapeutic action, diarrhea is the most common adverse event. © 2017, Springer International Publishing AG.
引用
收藏
页码:497 / 504
页数:7
相关论文
共 50 条
  • [31] Polyethylene Glycol in Constipation-Predominant Irritable Bowel Syndrome Response
    Chapman, R. W.
    Stanghellini, V.
    Geraint, M.
    Halphen, M.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 (01): : 136 - 136
  • [32] Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation
    Corsetti, Maura
    Tack, Jan
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2013, 1 (01) : 7 - 20
  • [33] Linaclotide: A Review of Its Use in the Treatment of Irritable Bowel Syndrome with Constipation
    Paul L. McCormack
    Drugs, 2014, 74 : 53 - 60
  • [34] Linaclotide: A Review of Its Use in the Treatment of Irritable Bowel Syndrome with Constipation
    McCormack, Paul L.
    DRUGS, 2014, 74 (01) : 53 - 60
  • [35] Linaclotide: a guide to its use in irritable bowel syndrome with constipation in the EU
    Yang L.P.H.
    McCormack P.L.
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2014, 30 (10) : 342 - 347
  • [36] The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
    Heidelbaugh, Joel J.
    Stelwagon, Margie
    Miller, Steve A.
    Shea, Elizabeth P.
    Chey, William D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (04): : 580 - 587
  • [37] Linaclotide approved for constipation-predominant IBS
    Katrina Ray
    Nature Reviews Gastroenterology & Hepatology, 2012, 9 (11) : 616 - 616
  • [38] Colonoscopic features of functional constipation and constipation-predominant irritable bowel syndrome (IBS-C)
    Takeshi, M.
    Hidekazu, S.
    Toshifumi, H.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 : 21 - 22
  • [39] The management of constipation-related functional gastrointestinal disorder (constipation-predominant irritable bowel syndrome)
    Amal F. Radwan
    Nagwa R. Ahmed
    Eman A. Sultan
    The Egyptian Journal of Internal Medicine, 2015, 27 (4) : 127 - 132
  • [40] Decoding Abdominal Pain in Constipation-predominant Irritable Bowel Syndrome and Functional Constipation: Mechanisms and Managements
    Jingyuan Luo
    Qianqian Xu
    Shujun Xu
    Lixiang Zhai
    Chun-Su Yuan
    Zhaoxiang Bian
    Current Gastroenterology Reports, 2025, 27 (1)